Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
Titel:
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
Auteur:
Yoo, Dae Hyun Suh, Chang-Hee Shim, Seung Cheol Jeka, Slawomir Molina, Francisco Fidencio Cons Hrycaj, Pawel Wiland, Piotr Lee, Eun Young Medina-Rodriguez, Francisco G. Shesternya, Pavel Radominski, Sebastiao Stanislav, Marina Kovalenko, Volodymyr Sheen, Dong Hyuk Myasoutova, Leysan Lim, Mie Jin Choe, Jung-Yoon Lee, Sang Joon Lee, Sung Young Kim, Sung Hwan Park, Won